The Centers for Disease Control and Prevention (CDC) announced Friday that results from the first two clinical trials of the Covid vaccine have been published in The Lancet and The Lancet Oncology.
The results of the trial, which began last week, involved approximately 8,000 Covid positive adults and children who were tested for CNV1 and CNV2 on a site in California.
Results from the other two trials, which are still ongoing, are scheduled to be published in March.
The findings, which appear to have been based on blood tests and lab results, are not yet available for public review, and the CDC has not yet released further details about the study.
The news of the first clinical trial’s findings came as part of a broader report released Friday that said there was limited evidence of a vaccine efficacy for people with CNV-19 who do not have the virus themselves.
The report concluded that “there is limited evidence that the CNV vaccine is safe and effective for people who do have CNV infection,” according to a statement.
It is unclear what, if any, additional data the researchers used to determine the vaccine’s effectiveness.
However, the CDC said in a statement that the findings support its recommendation to vaccinate against the virus.
While the vaccine was approved in the U.S. in early 2019, the results from this study are not expected to affect the approval of the vaccine for other countries, according to the statement.
The announcement comes after a string of events over the last two weeks that have made headlines in the United States and abroad.
On Monday, a report from the British government said that it has received preliminary evidence of the virus’s effectiveness against people who are not infected with CIV.
The report, which was commissioned by the U